ARO-APOC3
Phase 2Small molecule
Arrowhead PharmaceuticalsARO-APOC3 is one of 45 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Selzentry
GSKApproved
Lopid
PfizerApproved
Cipro
BayerApproved
Lovaza
AstraZenecaApproved
Zocor
OOrganon and Co
Approved
Topamax
WWim Janssens
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zetia
OOrganon and Co
Phase 3
Statin
Bristol-Myers SquibbPhase 3
EVKEEZA
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Familial Chylomicronemia Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARO-APOC3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company